Banque Pictet & Cie’s NovoCure NVCR Stock Holding History

Banque Pictet & Cie’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-750,000	Closed	-$11.2M	–	373
2023 Q4	$11.2M	Buy	+750,000	New	+$10M	0.09%	80

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Banque Pictet & Cie's NVCR Position: Q1 2024 in Review

Banque Pictet & Cie sold out of NovoCure (NVCR) in Q1 2024, closing a stake of 162,467 shares — an estimated $2.43M sold.

Banque Pictet & Cie first reported a position in NVCR in Q4 2021 and held it in 9 quarters. The position peaked at $22.5M in Q4 2021. 238 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

Banque Pictet & Cie reported no remaining NovoCure position as of Q1 2024 after selling out during the quarter.
Banque Pictet & Cie sold 162,467 NovoCure shares in Q1 2024, an estimated $2.43M.
Banque Pictet & Cie first reported a position in NovoCure in Q4 2021 and held it in 9 quarters.
Banque Pictet & Cie's NovoCure position peaked at $22.5M in Q4 2021.
238 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on Banque Pictet & Cie's 13F filing for Q1 2024, filed 6 May 2024.